50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,719.04 (+1.97%)
DOW   29,683.74 (+1.88%)
QQQ   279.94 (+1.99%)
AAPL   149.84 (-1.27%)
MSFT   241.07 (+1.97%)
META   141.61 (+5.36%)
GOOGL   100.05 (+2.62%)
AMZN   118.01 (+3.15%)
TSLA   287.81 (+1.72%)
NVDA   127.36 (+2.60%)
NIO   17.33 (+0.81%)
BABA   80.99 (+4.01%)
AMD   68.36 (+1.77%)
T   15.83 (+0.64%)
MU   51.00 (+0.83%)
CGC   3.04 (+6.29%)
F   12.18 (+2.27%)
GE   64.46 (-0.02%)
DIS   99.40 (+3.70%)
AMC   7.67 (+2.95%)
PYPL   91.12 (+6.26%)
PFE   44.43 (+0.77%)
NFLX   245.20 (+9.29%)
S&P 500   3,719.04 (+1.97%)
DOW   29,683.74 (+1.88%)
QQQ   279.94 (+1.99%)
AAPL   149.84 (-1.27%)
MSFT   241.07 (+1.97%)
META   141.61 (+5.36%)
GOOGL   100.05 (+2.62%)
AMZN   118.01 (+3.15%)
TSLA   287.81 (+1.72%)
NVDA   127.36 (+2.60%)
NIO   17.33 (+0.81%)
BABA   80.99 (+4.01%)
AMD   68.36 (+1.77%)
T   15.83 (+0.64%)
MU   51.00 (+0.83%)
CGC   3.04 (+6.29%)
F   12.18 (+2.27%)
GE   64.46 (-0.02%)
DIS   99.40 (+3.70%)
AMC   7.67 (+2.95%)
PYPL   91.12 (+6.26%)
PFE   44.43 (+0.77%)
NFLX   245.20 (+9.29%)
S&P 500   3,719.04 (+1.97%)
DOW   29,683.74 (+1.88%)
QQQ   279.94 (+1.99%)
AAPL   149.84 (-1.27%)
MSFT   241.07 (+1.97%)
META   141.61 (+5.36%)
GOOGL   100.05 (+2.62%)
AMZN   118.01 (+3.15%)
TSLA   287.81 (+1.72%)
NVDA   127.36 (+2.60%)
NIO   17.33 (+0.81%)
BABA   80.99 (+4.01%)
AMD   68.36 (+1.77%)
T   15.83 (+0.64%)
MU   51.00 (+0.83%)
CGC   3.04 (+6.29%)
F   12.18 (+2.27%)
GE   64.46 (-0.02%)
DIS   99.40 (+3.70%)
AMC   7.67 (+2.95%)
PYPL   91.12 (+6.26%)
PFE   44.43 (+0.77%)
NFLX   245.20 (+9.29%)
S&P 500   3,719.04 (+1.97%)
DOW   29,683.74 (+1.88%)
QQQ   279.94 (+1.99%)
AAPL   149.84 (-1.27%)
MSFT   241.07 (+1.97%)
META   141.61 (+5.36%)
GOOGL   100.05 (+2.62%)
AMZN   118.01 (+3.15%)
TSLA   287.81 (+1.72%)
NVDA   127.36 (+2.60%)
NIO   17.33 (+0.81%)
BABA   80.99 (+4.01%)
AMD   68.36 (+1.77%)
T   15.83 (+0.64%)
MU   51.00 (+0.83%)
CGC   3.04 (+6.29%)
F   12.18 (+2.27%)
GE   64.46 (-0.02%)
DIS   99.40 (+3.70%)
AMC   7.67 (+2.95%)
PYPL   91.12 (+6.26%)
PFE   44.43 (+0.77%)
NFLX   245.20 (+9.29%)
NASDAQ:SRPT

Sarepta Therapeutics - SRPT Stock Forecast, Price & News

$109.91
+1.58 (+1.46%)
(As of 09/28/2022 12:00 AM ET)
Add
Compare
Today's Range
$108.93
$111.00
50-Day Range
$82.54
$119.24
52-Week Range
$61.28
$120.23
Volume
743,495 shs
Average Volume
953,939 shs
Market Capitalization
$9.62 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$131.31

Sarepta Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
19.5% Upside
$131.31 Price Target
Short Interest
Bearish
7.79% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.65
Upright™ Environmental Score
News Sentiment
0.93mentions of Sarepta Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Acquiring Shares
$10.96 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($6.89) to ($4.86) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.91 out of 5 stars

Medical Sector

791st out of 1,096 stocks

Pharmaceutical Preparations Industry

386th out of 548 stocks

SRPT stock logo

About Sarepta Therapeutics (NASDAQ:SRPT) Stock

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Receive SRPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SRPT Stock News Headlines

SRPT Sarepta Therapeutics, Inc.
Sarepta prices almost $1 billion convertible bond offering
Sarepta (SRPT) Stock Up 76.8% in Three Months: Here's Why
5SRPT : Sarepta Therapeutics Whale Trades Spotted
See More Headlines
Receive SRPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SRPT Company Calendar

Last Earnings
11/03/2021
Today
9/28/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SRPT
Previous Symbol
NASDAQ:AVII
Employees
840
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$131.31
High Stock Price Forecast
$182.00
Low Stock Price Forecast
$90.00
Forecasted Upside/Downside
+19.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
12 Analysts

Profitability

Net Income
$-418,780,000.00
Pretax Margin
-60.11%

Debt

Sales & Book Value

Annual Sales
$701.89 million
Book Value
$10.66 per share

Miscellaneous

Free Float
81,964,000
Market Cap
$9.62 billion
Optionable
Optionable
Beta
1.20

Key Executives

  • Mr. Douglas S. Ingram Esq.Mr. Douglas S. Ingram Esq. (Age 59)
    Pres, CEO & Director
    Comp: $1.55M
  • Mr. Ian Michael Estepan (Age 46)
    Exec. VP & CFO
    Comp: $861.75k
  • Mr. William F. Ciambrone (Age 58)
    Exec. VP of Technical Operations
    Comp: $780.28k
  • Dr. Louise R. Rodino-Klapac Ph.D.Dr. Louise R. Rodino-Klapac Ph.D. (Age 44)
    Exec. VP, Chief Scientific Officer and Head of R&D
    Comp: $929.68k
  • Mr. Ryan E. Brown (Age 44)
    Sr. VP, Gen. Counsel & Corp. Sec.
    Comp: $913.64k
  • Mary Jenkins
    Sr. Mang. of Investor Relations
  • Ms. Alison Nasisi
    Chief People Officer & VP
  • Dr. Diane L. Berry
    Sr. VP of Global Health Policy and Gov. & Patient Affairs
  • Mr. Dallan Murray
    Sr. VP & Chief Customer Officer
  • Mr. Joseph Bratica (Age 58)
    Controller & VP













SRPT Stock - Frequently Asked Questions

Should I buy or sell Sarepta Therapeutics stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sarepta Therapeutics in the last twelve months. There are currently 3 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SRPT shares.
View SRPT analyst ratings
or view top-rated stocks.

What is Sarepta Therapeutics' stock price forecast for 2022?

12 brokers have issued twelve-month target prices for Sarepta Therapeutics' stock. Their SRPT share price forecasts range from $90.00 to $182.00. On average, they anticipate the company's share price to reach $131.31 in the next year. This suggests a possible upside of 19.5% from the stock's current price.
View analysts price targets for SRPT
or view top-rated stocks among Wall Street analysts.

How have SRPT shares performed in 2022?

Sarepta Therapeutics' stock was trading at $90.05 at the beginning of the year. Since then, SRPT stock has increased by 22.1% and is now trading at $109.91.
View the best growth stocks for 2022 here
.

When is Sarepta Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our SRPT earnings forecast
.

How were Sarepta Therapeutics' earnings last quarter?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) released its quarterly earnings results on Wednesday, November, 3rd. The biotechnology company reported ($0.60) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.86) by $1.26. The biotechnology company earned $189.41 million during the quarter, compared to analysts' expectations of $170.13 million. Sarepta Therapeutics had a negative net margin of 60.66% and a negative trailing twelve-month return on equity of 67.98%. During the same quarter in the prior year, the business posted ($2.50) EPS.

What guidance has Sarepta Therapeutics issued on next quarter's earnings?

Sarepta Therapeutics issued an update on its FY 2022 earnings guidance on Tuesday, August, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $905.00 million-$920.00 million, compared to the consensus revenue estimate of $899.91 million.

What is Douglas S. Ingram's approval rating as Sarepta Therapeutics' CEO?

15 employees have rated Sarepta Therapeutics Chief Executive Officer Douglas S. Ingram on Glassdoor.com. Douglas S. Ingram has an approval rating of 95% among the company's employees. This puts Douglas S. Ingram in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Sarepta Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sarepta Therapeutics investors own include Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV) and Walt Disney (DIS).

What is Sarepta Therapeutics' stock symbol?

Sarepta Therapeutics trades on the NASDAQ under the ticker symbol "SRPT."

Who are Sarepta Therapeutics' major shareholders?

Sarepta Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Sands Capital Management LLC (4.24%), Price T Rowe Associates Inc. MD (1.33%), Federated Hermes Inc. (0.80%), Casdin Capital LLC (0.74%), Frontier Capital Management Co. LLC (0.51%) and Assenagon Asset Management S.A. (0.51%). Insiders that own company stock include Alexander Cumbo, David T Howton, Douglas S Ingram, Hans Lennart Rudolf Wigzell, Joseph Bratica, Louise Rodino-Klapac, M Kathleen Behrens, Michael Andrew Chambers, Richard Barry and Sandesh Mahatme.
View institutional ownership trends
.

How do I buy shares of Sarepta Therapeutics?

Shares of SRPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sarepta Therapeutics' stock price today?

One share of SRPT stock can currently be purchased for approximately $109.91.

How much money does Sarepta Therapeutics make?

Sarepta Therapeutics (NASDAQ:SRPT) has a market capitalization of $9.62 billion and generates $701.89 million in revenue each year. The biotechnology company earns $-418,780,000.00 in net income (profit) each year or ($5.87) on an earnings per share basis.

How many employees does Sarepta Therapeutics have?

The company employs 840 workers across the globe.

How can I contact Sarepta Therapeutics?

Sarepta Therapeutics' mailing address is 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142. The official website for the company is www.sareptatherapeutics.com. The biotechnology company can be reached via phone at (857) 242-4000, via email at investors@sarepta.com, or via fax at 425-354-5038.

This page (NASDAQ:SRPT) was last updated on 9/28/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.